Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Documenti analoghi

• Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor
  di: Werner Leber, et al.
  Pubblicazione: (2021-10-01)
• Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
  di: Yuming Sun, et al.
  Pubblicazione: (2023-08-01)
• Corrigendum to “Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care” [EClinicalMedicine 28 (2020) 100,578]
  di: Paolo Fusar-Poli, et al.
  Pubblicazione: (2021-02-01)
• Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [EClinicalMedicine 37 (2021) 100,959]”
  di: Alejandro Krolewiecki, et al.
  Pubblicazione: (2021-09-01)
• Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
  di: Vinicius Fontanesi Blum, MD, MSc, et al.
  Pubblicazione: (2021-11-01)